Evidence map›Paper›PMID 38675171›Full record

ArticlePharmaceutics2024

Combination of the Topical Photodynamic Therapy of Chloroaluminum Phthalocyanine Liposomes with Fexinidazole Oral Self-Emulsifying System as a New Strategy for Cutaneous Leishmaniasis Treatment.

Raphaela Ariany Silva, Danielle Soter Damasio, Larissa Dutra Coelho, Eliane de Morais-Teixeira, Celso M Queiroz-Junior, Paulo Eduardo Souza, Ricardo Bentes Azevedo, Antônio Tedesco, Lucas Antônio Ferreira, Mônica Cristina Oliveira and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raphaela Ariany SilvaDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Danielle Soter DamasioDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Larissa Dutra CoelhoDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-4119-8696
Eliane de Morais-TeixeiraClinical Research and Public Policy Group on Infectious and Parasitic Diseases, Instituto René Rachou, Fundação Oswaldo Cruz-FIOCRUZ, Belo Horizonte 330190-002, Brazil.
Celso M Queiroz-JuniorDepartment of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Paulo Eduardo SouzaLaboratory of Software and Instrumentation in Applied Physics and Laboratory of Electron Paramagnetic Resonance, Institute of Physics, University of Brasília, Brasília 70910-900, Brazil.
Ricardo Bentes AzevedoNanobiotechnology Laboratory, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil.ORCID 0000-0002-2137-9588
Antônio TedescoDepartment of Chemistry, Center of Nanotechnology and Tissue Engineering-Photobiology and Photomedicine Research Group, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-900, Brazil.ORCID 0000-0003-4198-9321
Lucas Antônio FerreiraDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Mônica Cristina OliveiraDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Marta Gontijo AguiarDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-3820-2842

Funding

Fundação de Amparo à Pesquisa do Estado de Minas Gerais CDS-RED-00007-14National Council for Scientific and Technological Development 307098/2018National Council for Scientific and Technological Development 573880/2008-5
6 · The paper itself

Abstract

Cutaneous leishmaniasis (CL) is a neglected tropical disease. The treatment is restricted to drugs, such as meglumine antimoniate and amphotericin B, that exhibit toxic effects, high cost, long-term treatment, and limited efficacy. The development of new alternative therapies, including the identification of effective drugs for the topical and oral treatment of CL, is of great interest. In this sense, a combination of topical photodynamic therapy (PDT) with chloroaluminum phthalocyanine liposomes (Lip-ClAlPc) and the oral administration of a self-emulsifying drug delivery system containing fexinidazole (SEDDS-FEX) emerges as a new strategy. The aim of the present study was to prepare, characterize, and evaluate the efficacy of combined therapy with Lip-ClAlPc and SEDDS-FEX in the experimental treatment of

Indexed as

chloroaluminum phthalocyaninecombined therapycutaneous leishmaniasisfexinidazoleliposomesself-emulsifying drug release system

Identifiers

PMID38675171
PMCPMC11054953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.